Side-by-side · Research reference

GHK-CuvsLL-37

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/47 cited

BHuman-MechanisticHUMAN-REVIEWED15/35 cited

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

01Mechanism of Action

Parameter

GHK-Cu

LL-37

Primary target

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

Pathway

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

Downstream effect

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Feedback intact?

Replaces declining endogenous levels

—

Origin

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Antibody development

—

02Dosage Protocols

Parameter

GHK-Cu

LL-37

Standard SQ dose

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

—

Topical concentration

0.1–2.0% in serum / cream

—

Frequency

Daily or 2–3× per week (SQ)

—

Lower / starter dose

0.5 mg / day SQ

—

Evidence basis

Human-mechanistic + topical clinical studiesPickart 2018

In vitro, animal models, human observational

Duration

8–12 weeks for visible skin / hair effect

—

Reconstitution

Bacteriostatic water; light-protected

—

Timing

No specific time; evening preferred for topicals

—

Half-life

Hours (estimated; rapid tissue uptake)

—

Endogenous expression

—

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

Exogenous (experimental)

—

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

Plasma levels (malaria)

—

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

04Side Effects & Safety

Parameter

GHK-Cu

LL-37

Injection site reaction

Erythema, mild pruritus (common)

—

Topical irritation

Mild redness, transient stinging

—

Copper accumulation

Theoretical with very high chronic doses

—

Allergic reaction

Rare hypersensitivity to copper

—

Pregnancy / OB

Avoid topical and SQ — insufficient data

—

Wilson disease

Contraindicated

—

Cytotoxicity (high dose)

—

Membrane disruption in host cells at supraphysiological concentrations

Pro-inflammatory signaling

—

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

Biofilm formation risk

—

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

Theoretical cancer risk

—

Immunomodulatory roles in tumor microenvironment under investigation

Absolute Contraindications

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

LL-37

—

Relative Contraindications

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

05Administration Protocol

Parameter

GHK-Cu

LL-37

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

2. Injection site

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

3. Timing

Anytime; evening preferred. Topical: apply to clean dry skin.

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

—

5. Needle

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

—

06Stack Synergy

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair

LL-37

— no documented stacks